Given that GLP-1RAs exert beneficial effects on risk factors for new-onset AF (e.g., body weight, blood pressure, renal function, and glycemic control), their impact on AF events has emerged as an area of growing interest in academia and clinical settings (118, 119)
Neumiller: Teplizumab is the first FDA-approved agent to delay the onset of type 1 diabetes in at-risk individuals
Las sociedades mdicas estn trabajando intensamente para desarrollar nuevas directrices que ayuden a los mdicos a utilizar estos medicamentos de forma segura y eficaz en la prctica clnica.
Comparisons between more than two experimental groups were performed by one-way or two-way ANOVA when the variable time is considered, since we analyzed the effect of two or more different categorical independent variables (genotype and/or treatment) on one continuous dependent variable (time)
The American Diabetes Association (ADA) recommends GLP-1 RAs in patients with clinical characteristics like presence of established ASCVD and cardiac heart failure or chronic kidney diseases [15]
Semaglutide achieved substantial but smaller clinical benefit
